Trimbow

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Beclometasone дипропионат, формотерола фумарата dihidrat bromid Glycopyrronium

Available from:

Chiesi Farmaceutici S.p.A.

ATC code:

R03AL09

INN (International Name):

beclometasone, formoterol, glycopyrronium bromide

Therapeutic group:

Lijekovi za opstruktivne plućne bolesti dišnih putova,

Therapeutic area:

Plućna bolest, kronična opstruktivna

Therapeutic indications:

Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Product summary:

Revision: 7

Authorization status:

odobren

Authorization date:

2017-07-17

Patient Information leaflet

                                95
B. UPUTA O LIJEKU
96
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
TRIMBOW 87 MIKROGRAMA/5 MIKROGRAMA/9 MIKROGRAMA STLAČENI INHALAT,
OTOPINA
beklometazondipropionat/formoterolfumarat dihidrat/glikopironij
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Trimbow i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati Trimbow
3.
Kako primjenjivati Trimbow
4.
Moguće nuspojave
5.
Kako čuvati Trimbow
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE TRIMBOW I ZA ŠTO SE KORISTI
Trimbow je lijek za olakšavanje disanja koji sadrži tri djelatne
tvari:
•
beklometazondipropionat,
•
formoterolfumarat dihidrat i
•
glikopironij.
Beklometazondipropionat pripada skupini lijekova koji se nazivaju
kortikosteroidi i djeluju tako što
smanjuju oticanje i nadraženost u plućima.
Formoterol i glikopironij su lijekovi koji se nazivaju dugodjelujući
bronhodilatatori. Oni na različite
načine opuštaju mišiće dišnih puteva, tako ih proširuju te Vam
omogućuju da lakše dišete.
Redovito liječenje pomoću ove tri djelatne tvari pomaže olakšati i
spriječiti simptome poput
nedostatka zraka, piskanja pri disanju i kašlja u odraslih bolesnika
s opstruktivnom plućnom bolešću.
Trimbow se primjenjuje za redovito liječenje
•
kronične opstruktivne plućne bolest (KOPB) u odraslih
•
astme u odraslih.
Trimbow može smanjiti egzacerbacije (razbuktavanje) simptoma KOPB-a i
astme.
KOPB je ozbiljna dugotrajna bolest u kojoj dolazi do začepljenja
di
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Trimbow 87 mikrograma/5 mikrograma/9 mikrograma stlačeni inhalat,
otopina
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna isporučena doza (doza koja izađe iz nastavka za usta) sadrži
87 mikrograma
beklometazondipropionata, 5 mikrograma formoterolfumarat dihidrata i 9
mikrograma glikopironija (u
obliku 11 mikrograma glikopironijevog bromida).
Jedna odmjerena doza (doza koja izađe iz ventila) sadrži 100
mikrograma beklometazondipropionata,
6 mikrograma formoterolfumarat dihidrata i 10 mikrograma glikopironija
(u obliku 12,5 mikrograma
glikopironijevog bromida).
Pomoćna tvar s poznatim učinkom:
_ _
Trimbow sadrži 8,856 mg etanola po potisku.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Stlačeni inhalat, otopina (stlačeni inhalat)
Bezbojna do žućkasta otopina.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Kronična opstruktivna plućna bolest (KOPB)
Terapija održavanja u odraslih bolesnika s umjerenim do teškim
KOPB-om koji nisu odgovarajuće
liječeni kombinacijom inhalacijskog kortikosteroida i dugodjelujućeg
beta-2 agonista ili
kombinacijom dugodjelujućeg beta-2 agonista i dugodjelujućeg
muskarinskog antagonista (za učinke
na kontrolu simptoma i sprječavanje egzacerbacija vidjeti dio 5.1).
Astma
Terapija održavanja u odraslih s astmom koja nije odgovarajuće
kontrolirana kombiniranom terapijom
održavanja dugodjelujućim beta-2 agonistom i srednjom dozom
inhalacijskog kortikosteroida i koji su
u prethodnih godinu dana imali jednu ili više egzacerbacija astme.
4.2
DOZIRANJE I NAČIN PRIMJENE
Doziranje
Preporučena doza je dva udaha dva puta na dan.
Maksimalna doza je dva udaha dva puta na dan.
Bolesnicima treba savjetovati da uzimaju Trimbow svakog dana, čak i
kad nemaju simptome.
Ako se u razdoblju između primjena doza pojave simptomi, za brzo
ublažavanje simptoma treba
primijeniti inhalacijski kratkodjelujući beta-2 agonist.
3
_Astma _
Kad se odabire početna jačina doze lijeka Trimbow (87/5/9 mikrog
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-04-2022
Public Assessment Report Public Assessment Report Bulgarian 26-02-2021
Patient Information leaflet Patient Information leaflet Spanish 01-04-2022
Public Assessment Report Public Assessment Report Spanish 26-02-2021
Patient Information leaflet Patient Information leaflet Czech 01-04-2022
Public Assessment Report Public Assessment Report Czech 26-02-2021
Patient Information leaflet Patient Information leaflet Danish 01-04-2022
Public Assessment Report Public Assessment Report Danish 26-02-2021
Patient Information leaflet Patient Information leaflet German 01-04-2022
Public Assessment Report Public Assessment Report German 26-02-2021
Patient Information leaflet Patient Information leaflet Estonian 01-04-2022
Public Assessment Report Public Assessment Report Estonian 26-02-2021
Patient Information leaflet Patient Information leaflet Greek 01-04-2022
Public Assessment Report Public Assessment Report Greek 26-02-2021
Patient Information leaflet Patient Information leaflet English 01-04-2022
Public Assessment Report Public Assessment Report English 26-02-2021
Patient Information leaflet Patient Information leaflet French 01-04-2022
Public Assessment Report Public Assessment Report French 26-02-2021
Patient Information leaflet Patient Information leaflet Italian 01-04-2022
Public Assessment Report Public Assessment Report Italian 26-02-2021
Patient Information leaflet Patient Information leaflet Latvian 01-04-2022
Public Assessment Report Public Assessment Report Latvian 26-02-2021
Patient Information leaflet Patient Information leaflet Lithuanian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-04-2022
Public Assessment Report Public Assessment Report Lithuanian 26-02-2021
Patient Information leaflet Patient Information leaflet Hungarian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 01-04-2022
Public Assessment Report Public Assessment Report Hungarian 26-02-2021
Patient Information leaflet Patient Information leaflet Maltese 01-04-2022
Public Assessment Report Public Assessment Report Maltese 26-02-2021
Patient Information leaflet Patient Information leaflet Dutch 01-04-2022
Public Assessment Report Public Assessment Report Dutch 26-02-2021
Patient Information leaflet Patient Information leaflet Polish 01-04-2022
Public Assessment Report Public Assessment Report Polish 26-02-2021
Patient Information leaflet Patient Information leaflet Portuguese 01-04-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 01-04-2022
Public Assessment Report Public Assessment Report Portuguese 26-02-2021
Patient Information leaflet Patient Information leaflet Romanian 01-04-2022
Public Assessment Report Public Assessment Report Romanian 26-02-2021
Patient Information leaflet Patient Information leaflet Slovak 01-04-2022
Public Assessment Report Public Assessment Report Slovak 26-02-2021
Patient Information leaflet Patient Information leaflet Slovenian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 01-04-2022
Public Assessment Report Public Assessment Report Slovenian 26-02-2021
Patient Information leaflet Patient Information leaflet Finnish 01-04-2022
Public Assessment Report Public Assessment Report Finnish 26-02-2021
Patient Information leaflet Patient Information leaflet Swedish 01-04-2022
Public Assessment Report Public Assessment Report Swedish 26-02-2021
Patient Information leaflet Patient Information leaflet Norwegian 01-04-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 01-04-2022
Patient Information leaflet Patient Information leaflet Icelandic 01-04-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 01-04-2022

View documents history